Company History
Mucosis was founded in 2007 and is built on the proprietary Mimopath® vaccine technology platform. The technology counts its origin at the Department of Molecular Genetics at the University of Groningen and Biomade Technology Foundation, the Netherlands. The company successfully secured funding (including non-dilutive) to advance its proof-of-concept program, FluGEM®, into a Phase I human clinical study in 2011 and to further develop its proprietary mucosal vaccine technology platform including its lead programs SynGEM and PneuGEM towards the clinic.
16.05.13 Mucosis presents preclinical data demonstrating protection by its intranasal SynGEM® RSV vaccine candidate
more >
08.10.12 Mucosis signs Research and License Option Agreement with Crucell
more >
25.09.12 ExpreS²ion, Mucosis, and University of Copenhagen receive Eurostars grant
more >
18.09.12 Mucosis Appoints Thomas Johnston to CEO
more >
10.05.12 Mucosis announces positive proof-of-concept data for Mimopath® platform in humans
more >
03.05.12 Mucosis announces publication of preclinical data demonstrating...
more >
15.11.11 Mucosis announces new scientific advisory board
more >
17.05.11 Mucosis appoints Thomas Johnston as Chief Business Officer
more >
